title: A transmembrane domain-derived peptide inhibits D1 dopamine receptor function without affecting receptor oligomerization.
abstract: In this study, we show that a peptide based on the sequence of transmembrane domain 6 of the D1 dopamine receptor (D1DR) specifically inhibited D1DR binding and function, without affecting receptor oligomerization. It has been shown that an analogous peptide from the beta2-adrenergic receptor disrupted dimerization and adenylyl cyclase activation in the beta2-adrenergic receptor (Hebert, T. E., Moffett, S., Morello, J. P., Loisel, T. P., Bichet, D. G., Barret, C., and Bouvier, M. (1996) J. Biol. Chem. 271, 16384-16392). Treatment of D1DR with the D1DR transmembrane 6 peptide resulted in a dose-dependent, irreversible inhibition of D1DR antagonist binding, an effect not seen in D1DR with peptides based on transmembrane domains of other G protein-coupled receptors. Incubation with the D1DR transmembrane 6 peptide also resulted in a dose-dependent attenuation of both dopamine-induced [35S]guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) binding and receptor-mediated dopamine stimulation of adenylyl cyclase activity. Notably, GTPgammaS binding and cAMP production were reduced to levels below baseline, indicating blockade of ligand-independent, intrinsic receptor activity. Immunoblot analyses of the D1DR revealed the receptor existed as monomers, dimers, and higher order oligomers and that these oligomeric states were unaffected after incubation with the D1DR transmembrane 6 peptide. These findings represent the first demonstration that a peptide based on the transmembrane 6 of the D1DR may represent a novel category of noncompetitive D1DR antagonists.
authors.affiliation: Department of Pharmacology, University of Toronto, Toronto, Ontario M5S 1A8, Canada. s.george@utoronto.ca
authors.forename: S R
authors.initials: SR
authors.lastname: George
authors.forename: S P
authors.initials: SP
authors.lastname: Lee
authors.forename: G
authors.initials: G
authors.lastname: Varghese
authors.forename: P R
authors.initials: PR
authors.lastname: Zeman
authors.forename: P
authors.initials: P
authors.lastname: Seeman
authors.forename: G Y
authors.initials: GY
authors.lastname: Ng
authors.forename: B F
authors.initials: BF
authors.lastname: O'Dowd
mesh_terms: D000818:Animals; D001552:Benzazepines / Q000378:metabolism; D002478:Cells, Cultured; D019281:Dimerization; D018492:Dopamine Antagonists / Q000378:metabolism; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000378:metabolism; D007700:Kinetics; D010446:Peptide Fragments / Q000378:metabolism*; D011108:Polymers / Q000378:metabolism; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors* / Q000737:chemistry; D018411:Spodoptera
chemical_list: D001552:Benzazepines; D018492:Dopamine Antagonists; D010446:Peptide Fragments; D011108:Polymers; D017447:Receptors, Dopamine D1; D016244:Guanosine 5'-O-(3-Thiotriphosphate)